Mechanisms predictive of Tibetan Medicine Sophora moorcroftiana alkaloids for treatment of lung cancer based on the network pharmacology and molecular docking
Leguminous Sophora moorcroftiana (SM) is a genuine medicinal material in Tibet. Many research results have reveal the Sophora moorcroftiana alkaloids (SMA), as the main active substance, have a wide range of effects, such as antibacterial, antitumor and antiparasitic effects. However, there are few...
Saved in:
| Published in | BMC complementary and alternative medicine Vol. 24; no. 1; p. 47 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
20.01.2024
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Leguminous Sophora moorcroftiana (SM) is a genuine medicinal material in Tibet. Many research results have reveal the Sophora moorcroftiana alkaloids (SMA), as the main active substance, have a wide range of effects, such as antibacterial, antitumor and antiparasitic effects. However, there are few reports on the inhibition of lung cancer (LC) and its inhibitory mechanism, and the pharmacological mechanism of SMA is still unclear, Therefore, exploring its mechanism of action is of great significance.
The SMA active components were obtained from the literature database. Whereas the corresponding targets were screened from the PubChem and PharmMapper database, UniProt database were conducted the correction and transformation of UniProt ID on the obtained targets. The GeneCards and OMIM databases identified targets associated with LC. Venny tools obtained the intersection targets of SMA and LC. R language and Cytoscape software constructed the visual of SMA - intersection targets - LC disease network. The intersection targets protein-protein interaction (PPI) network were built by the STRING database. The functions and pathways of the common targets of SMA and LC were enriched by gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG). Subsequently, molecular docking And A549 cells vitro experiment were performed to further validate our finding.
We obtained six kinds of alkaloids in SM, 635 potential targets for these compounds, and 1,303 genes related to LC. SMA and LC intersection targets was 33, including ALB, CCND1, ESR1, NOTCH1 and AR. GO enrichment indicated that biological process of SMA was mainly involved in the positive regulation of transcription and nitric oxide biosynthetic process, and DNA-templated, etc. Biological functions were mainly involved in transcription factor binding and enzyme binding, etc. Cell components were mainly involved in protein complexes, extracellular exosome, cytoplasm and nuclear chromatin, etc., Which may be associated with its anti-LC effects. KEGG enrichment analysis showed that main pathways involved in the anti-LC effects of SMA, including pathway in cancer, non small-cell lung cancer, p53, PI3K-Akt and FOXO signaling pathways. Molecular docking analyses revealed that the six active compounds had a good binding activity with the main therapeutic targets 2W96, 2CCH and 1O96. Experiments in vitro proved that SMA inhibited the proliferation of LC A549 cells.
Results of the present study, we have successfully revealed the SMA compounds had a multi-target and multi-channel regulatory mechanism in treatment LC, These findings provided a solid theoretical reference of SMA in the clinical treatment of LC. |
|---|---|
| AbstractList | BACKGROUND: Leguminous Sophora moorcroftiana (SM) is a genuine medicinal material in Tibet. Many research results have reveal the Sophora moorcroftiana alkaloids (SMA), as the main active substance, have a wide range of effects, such as antibacterial, antitumor and antiparasitic effects. However, there are few reports on the inhibition of lung cancer (LC) and its inhibitory mechanism, and the pharmacological mechanism of SMA is still unclear, Therefore, exploring its mechanism of action is of great significance. METHODS: The SMA active components were obtained from the literature database. Whereas the corresponding targets were screened from the PubChem and PharmMapper database, UniProt database were conducted the correction and transformation of UniProt ID on the obtained targets. The GeneCards and OMIM databases identified targets associated with LC. Venny tools obtained the intersection targets of SMA and LC. R language and Cytoscape software constructed the visual of SMA - intersection targets – LC disease network. The intersection targets protein-protein interaction (PPI) network were built by the STRING database. The functions and pathways of the common targets of SMA and LC were enriched by gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG). Subsequently, molecular docking And A549 cells vitro experiment were performed to further validate our finding. RESULTS: We obtained six kinds of alkaloids in SM, 635 potential targets for these compounds, and 1,303 genes related to LC. SMA and LC intersection targets was 33, including ALB, CCND1, ESR1, NOTCH1 and AR. GO enrichment indicated that biological process of SMA was mainly involved in the positive regulation of transcription and nitric oxide biosynthetic process, and DNA-templated, etc. Biological functions were mainly involved in transcription factor binding and enzyme binding, etc. Cell components were mainly involved in protein complexes, extracellular exosome, cytoplasm and nuclear chromatin, etc., Which may be associated with its anti-LC effects. KEGG enrichment analysis showed that main pathways involved in the anti-LC effects of SMA, including pathway in cancer, non small-cell lung cancer, p53, PI3K-Akt and FOXO signaling pathways. Molecular docking analyses revealed that the six active compounds had a good binding activity with the main therapeutic targets 2W96, 2CCH and 1O96. Experiments in vitro proved that SMA inhibited the proliferation of LC A549 cells. CONCLUSIONS: Results of the present study, we have successfully revealed the SMA compounds had a multi-target and multi-channel regulatory mechanism in treatment LC, These findings provided a solid theoretical reference of SMA in the clinical treatment of LC. Background Leguminous Sophora moorcroftiana (SM) is a genuine medicinal material in Tibet. Many research results have reveal the Sophora moorcroftiana alkaloids (SMA), as the main active substance, have a wide range of effects, such as antibacterial, antitumor and antiparasitic effects. However, there are few reports on the inhibition of lung cancer (LC) and its inhibitory mechanism, and the pharmacological mechanism of SMA is still unclear, Therefore, exploring its mechanism of action is of great significance. Methods The SMA active components were obtained from the literature database. Whereas the corresponding targets were screened from the PubChem and PharmMapper database, UniProt database were conducted the correction and transformation of UniProt ID on the obtained targets. The GeneCards and OMIM databases identified targets associated with LC. Venny tools obtained the intersection targets of SMA and LC. R language and Cytoscape software constructed the visual of SMA - intersection targets - LC disease network. The intersection targets protein-protein interaction (PPI) network were built by the STRING database. The functions and pathways of the common targets of SMA and LC were enriched by gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG). Subsequently, molecular docking And A549 cells vitro experiment were performed to further validate our finding. Results We obtained six kinds of alkaloids in SM, 635 potential targets for these compounds, and 1,303 genes related to LC. SMA and LC intersection targets was 33, including ALB, CCND1, ESR1, NOTCH1 and AR. GO enrichment indicated that biological process of SMA was mainly involved in the positive regulation of transcription and nitric oxide biosynthetic process, and DNA-templated, etc. Biological functions were mainly involved in transcription factor binding and enzyme binding, etc. Cell components were mainly involved in protein complexes, extracellular exosome, cytoplasm and nuclear chromatin, etc., Which may be associated with its anti-LC effects. KEGG enrichment analysis showed that main pathways involved in the anti-LC effects of SMA, including pathway in cancer, non small-cell lung cancer, p53, PI3K-Akt and FOXO signaling pathways. Molecular docking analyses revealed that the six active compounds had a good binding activity with the main therapeutic targets 2W96, 2CCH and 1O96. Experiments in vitro proved that SMA inhibited the proliferation of LC A549 cells. Conclusions Results of the present study, we have successfully revealed the SMA compounds had a multi-target and multi-channel regulatory mechanism in treatment LC, These findings provided a solid theoretical reference of SMA in the clinical treatment of LC. Keywords: Sophora Moorcroftiana, Alkaloids, Lung cancer, Network pharmacology, Molecular docking, Vitro Verification BackgroundLeguminous Sophora moorcroftiana (SM) is a genuine medicinal material in Tibet. Many research results have reveal the Sophora moorcroftiana alkaloids (SMA), as the main active substance, have a wide range of effects, such as antibacterial, antitumor and antiparasitic effects. However, there are few reports on the inhibition of lung cancer (LC) and its inhibitory mechanism, and the pharmacological mechanism of SMA is still unclear, Therefore, exploring its mechanism of action is of great significance.MethodsThe SMA active components were obtained from the literature database. Whereas the corresponding targets were screened from the PubChem and PharmMapper database, UniProt database were conducted the correction and transformation of UniProt ID on the obtained targets. The GeneCards and OMIM databases identified targets associated with LC. Venny tools obtained the intersection targets of SMA and LC. R language and Cytoscape software constructed the visual of SMA - intersection targets – LC disease network. The intersection targets protein-protein interaction (PPI) network were built by the STRING database. The functions and pathways of the common targets of SMA and LC were enriched by gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG). Subsequently, molecular docking And A549 cells vitro experiment were performed to further validate our finding.ResultsWe obtained six kinds of alkaloids in SM, 635 potential targets for these compounds, and 1,303 genes related to LC. SMA and LC intersection targets was 33, including ALB, CCND1, ESR1, NOTCH1 and AR. GO enrichment indicated that biological process of SMA was mainly involved in the positive regulation of transcription and nitric oxide biosynthetic process, and DNA-templated, etc. Biological functions were mainly involved in transcription factor binding and enzyme binding, etc. Cell components were mainly involved in protein complexes, extracellular exosome, cytoplasm and nuclear chromatin, etc., Which may be associated with its anti-LC effects. KEGG enrichment analysis showed that main pathways involved in the anti-LC effects of SMA, including pathway in cancer, non small-cell lung cancer, p53, PI3K-Akt and FOXO signaling pathways. Molecular docking analyses revealed that the six active compounds had a good binding activity with the main therapeutic targets 2W96, 2CCH and 1O96. Experiments in vitro proved that SMA inhibited the proliferation of LC A549 cells.ConclusionsResults of the present study, we have successfully revealed the SMA compounds had a multi-target and multi-channel regulatory mechanism in treatment LC, These findings provided a solid theoretical reference of SMA in the clinical treatment of LC. Leguminous Sophora moorcroftiana (SM) is a genuine medicinal material in Tibet. Many research results have reveal the Sophora moorcroftiana alkaloids (SMA), as the main active substance, have a wide range of effects, such as antibacterial, antitumor and antiparasitic effects. However, there are few reports on the inhibition of lung cancer (LC) and its inhibitory mechanism, and the pharmacological mechanism of SMA is still unclear, Therefore, exploring its mechanism of action is of great significance. The SMA active components were obtained from the literature database. Whereas the corresponding targets were screened from the PubChem and PharmMapper database, UniProt database were conducted the correction and transformation of UniProt ID on the obtained targets. The GeneCards and OMIM databases identified targets associated with LC. Venny tools obtained the intersection targets of SMA and LC. R language and Cytoscape software constructed the visual of SMA - intersection targets - LC disease network. The intersection targets protein-protein interaction (PPI) network were built by the STRING database. The functions and pathways of the common targets of SMA and LC were enriched by gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG). Subsequently, molecular docking And A549 cells vitro experiment were performed to further validate our finding. We obtained six kinds of alkaloids in SM, 635 potential targets for these compounds, and 1,303 genes related to LC. SMA and LC intersection targets was 33, including ALB, CCND1, ESR1, NOTCH1 and AR. GO enrichment indicated that biological process of SMA was mainly involved in the positive regulation of transcription and nitric oxide biosynthetic process, and DNA-templated, etc. Biological functions were mainly involved in transcription factor binding and enzyme binding, etc. Cell components were mainly involved in protein complexes, extracellular exosome, cytoplasm and nuclear chromatin, etc., Which may be associated with its anti-LC effects. KEGG enrichment analysis showed that main pathways involved in the anti-LC effects of SMA, including pathway in cancer, non small-cell lung cancer, p53, PI3K-Akt and FOXO signaling pathways. Molecular docking analyses revealed that the six active compounds had a good binding activity with the main therapeutic targets 2W96, 2CCH and 1O96. Experiments in vitro proved that SMA inhibited the proliferation of LC A549 cells. Leguminous Sophora moorcroftiana (SM) is a genuine medicinal material in Tibet. Many research results have reveal the Sophora moorcroftiana alkaloids (SMA), as the main active substance, have a wide range of effects, such as antibacterial, antitumor and antiparasitic effects. However, there are few reports on the inhibition of lung cancer (LC) and its inhibitory mechanism, and the pharmacological mechanism of SMA is still unclear, Therefore, exploring its mechanism of action is of great significance. The SMA active components were obtained from the literature database. Whereas the corresponding targets were screened from the PubChem and PharmMapper database, UniProt database were conducted the correction and transformation of UniProt ID on the obtained targets. The GeneCards and OMIM databases identified targets associated with LC. Venny tools obtained the intersection targets of SMA and LC. R language and Cytoscape software constructed the visual of SMA - intersection targets - LC disease network. The intersection targets protein-protein interaction (PPI) network were built by the STRING database. The functions and pathways of the common targets of SMA and LC were enriched by gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG). Subsequently, molecular docking And A549 cells vitro experiment were performed to further validate our finding. We obtained six kinds of alkaloids in SM, 635 potential targets for these compounds, and 1,303 genes related to LC. SMA and LC intersection targets was 33, including ALB, CCND1, ESR1, NOTCH1 and AR. GO enrichment indicated that biological process of SMA was mainly involved in the positive regulation of transcription and nitric oxide biosynthetic process, and DNA-templated, etc. Biological functions were mainly involved in transcription factor binding and enzyme binding, etc. Cell components were mainly involved in protein complexes, extracellular exosome, cytoplasm and nuclear chromatin, etc., Which may be associated with its anti-LC effects. KEGG enrichment analysis showed that main pathways involved in the anti-LC effects of SMA, including pathway in cancer, non small-cell lung cancer, p53, PI3K-Akt and FOXO signaling pathways. Molecular docking analyses revealed that the six active compounds had a good binding activity with the main therapeutic targets 2W96, 2CCH and 1O96. Experiments in vitro proved that SMA inhibited the proliferation of LC A549 cells. Results of the present study, we have successfully revealed the SMA compounds had a multi-target and multi-channel regulatory mechanism in treatment LC, These findings provided a solid theoretical reference of SMA in the clinical treatment of LC. Abstract Background Leguminous Sophora moorcroftiana (SM) is a genuine medicinal material in Tibet. Many research results have reveal the Sophora moorcroftiana alkaloids (SMA), as the main active substance, have a wide range of effects, such as antibacterial, antitumor and antiparasitic effects. However, there are few reports on the inhibition of lung cancer (LC) and its inhibitory mechanism, and the pharmacological mechanism of SMA is still unclear, Therefore, exploring its mechanism of action is of great significance. Methods The SMA active components were obtained from the literature database. Whereas the corresponding targets were screened from the PubChem and PharmMapper database, UniProt database were conducted the correction and transformation of UniProt ID on the obtained targets. The GeneCards and OMIM databases identified targets associated with LC. Venny tools obtained the intersection targets of SMA and LC. R language and Cytoscape software constructed the visual of SMA - intersection targets – LC disease network. The intersection targets protein-protein interaction (PPI) network were built by the STRING database. The functions and pathways of the common targets of SMA and LC were enriched by gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG). Subsequently, molecular docking And A549 cells vitro experiment were performed to further validate our finding. Results We obtained six kinds of alkaloids in SM, 635 potential targets for these compounds, and 1,303 genes related to LC. SMA and LC intersection targets was 33, including ALB, CCND1, ESR1, NOTCH1 and AR. GO enrichment indicated that biological process of SMA was mainly involved in the positive regulation of transcription and nitric oxide biosynthetic process, and DNA-templated, etc. Biological functions were mainly involved in transcription factor binding and enzyme binding, etc. Cell components were mainly involved in protein complexes, extracellular exosome, cytoplasm and nuclear chromatin, etc., Which may be associated with its anti-LC effects. KEGG enrichment analysis showed that main pathways involved in the anti-LC effects of SMA, including pathway in cancer, non small-cell lung cancer, p53, PI3K-Akt and FOXO signaling pathways. Molecular docking analyses revealed that the six active compounds had a good binding activity with the main therapeutic targets 2W96, 2CCH and 1O96. Experiments in vitro proved that SMA inhibited the proliferation of LC A549 cells. Conclusions Results of the present study, we have successfully revealed the SMA compounds had a multi-target and multi-channel regulatory mechanism in treatment LC, These findings provided a solid theoretical reference of SMA in the clinical treatment of LC. Leguminous Sophora moorcroftiana (SM) is a genuine medicinal material in Tibet. Many research results have reveal the Sophora moorcroftiana alkaloids (SMA), as the main active substance, have a wide range of effects, such as antibacterial, antitumor and antiparasitic effects. However, there are few reports on the inhibition of lung cancer (LC) and its inhibitory mechanism, and the pharmacological mechanism of SMA is still unclear, Therefore, exploring its mechanism of action is of great significance.BACKGROUNDLeguminous Sophora moorcroftiana (SM) is a genuine medicinal material in Tibet. Many research results have reveal the Sophora moorcroftiana alkaloids (SMA), as the main active substance, have a wide range of effects, such as antibacterial, antitumor and antiparasitic effects. However, there are few reports on the inhibition of lung cancer (LC) and its inhibitory mechanism, and the pharmacological mechanism of SMA is still unclear, Therefore, exploring its mechanism of action is of great significance.The SMA active components were obtained from the literature database. Whereas the corresponding targets were screened from the PubChem and PharmMapper database, UniProt database were conducted the correction and transformation of UniProt ID on the obtained targets. The GeneCards and OMIM databases identified targets associated with LC. Venny tools obtained the intersection targets of SMA and LC. R language and Cytoscape software constructed the visual of SMA - intersection targets - LC disease network. The intersection targets protein-protein interaction (PPI) network were built by the STRING database. The functions and pathways of the common targets of SMA and LC were enriched by gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG). Subsequently, molecular docking And A549 cells vitro experiment were performed to further validate our finding.METHODSThe SMA active components were obtained from the literature database. Whereas the corresponding targets were screened from the PubChem and PharmMapper database, UniProt database were conducted the correction and transformation of UniProt ID on the obtained targets. The GeneCards and OMIM databases identified targets associated with LC. Venny tools obtained the intersection targets of SMA and LC. R language and Cytoscape software constructed the visual of SMA - intersection targets - LC disease network. The intersection targets protein-protein interaction (PPI) network were built by the STRING database. The functions and pathways of the common targets of SMA and LC were enriched by gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG). Subsequently, molecular docking And A549 cells vitro experiment were performed to further validate our finding.We obtained six kinds of alkaloids in SM, 635 potential targets for these compounds, and 1,303 genes related to LC. SMA and LC intersection targets was 33, including ALB, CCND1, ESR1, NOTCH1 and AR. GO enrichment indicated that biological process of SMA was mainly involved in the positive regulation of transcription and nitric oxide biosynthetic process, and DNA-templated, etc. Biological functions were mainly involved in transcription factor binding and enzyme binding, etc. Cell components were mainly involved in protein complexes, extracellular exosome, cytoplasm and nuclear chromatin, etc., Which may be associated with its anti-LC effects. KEGG enrichment analysis showed that main pathways involved in the anti-LC effects of SMA, including pathway in cancer, non small-cell lung cancer, p53, PI3K-Akt and FOXO signaling pathways. Molecular docking analyses revealed that the six active compounds had a good binding activity with the main therapeutic targets 2W96, 2CCH and 1O96. Experiments in vitro proved that SMA inhibited the proliferation of LC A549 cells.RESULTSWe obtained six kinds of alkaloids in SM, 635 potential targets for these compounds, and 1,303 genes related to LC. SMA and LC intersection targets was 33, including ALB, CCND1, ESR1, NOTCH1 and AR. GO enrichment indicated that biological process of SMA was mainly involved in the positive regulation of transcription and nitric oxide biosynthetic process, and DNA-templated, etc. Biological functions were mainly involved in transcription factor binding and enzyme binding, etc. Cell components were mainly involved in protein complexes, extracellular exosome, cytoplasm and nuclear chromatin, etc., Which may be associated with its anti-LC effects. KEGG enrichment analysis showed that main pathways involved in the anti-LC effects of SMA, including pathway in cancer, non small-cell lung cancer, p53, PI3K-Akt and FOXO signaling pathways. Molecular docking analyses revealed that the six active compounds had a good binding activity with the main therapeutic targets 2W96, 2CCH and 1O96. Experiments in vitro proved that SMA inhibited the proliferation of LC A549 cells.Results of the present study, we have successfully revealed the SMA compounds had a multi-target and multi-channel regulatory mechanism in treatment LC, These findings provided a solid theoretical reference of SMA in the clinical treatment of LC.CONCLUSIONSResults of the present study, we have successfully revealed the SMA compounds had a multi-target and multi-channel regulatory mechanism in treatment LC, These findings provided a solid theoretical reference of SMA in the clinical treatment of LC. |
| ArticleNumber | 47 |
| Audience | Academic |
| Author | Ji, Peng Yao, Wan-Ling Wu, Fan-Lin Wujin, Cuo-Mu Hua, Yong-Li Wei, Yan-Ming Zhao, Nian-Shou Laba, Ci-Dan Yuan, Zi-Wen |
| Author_xml | – sequence: 1 givenname: Peng surname: Ji fullname: Ji, Peng – sequence: 2 givenname: Nian-Shou surname: Zhao fullname: Zhao, Nian-Shou – sequence: 3 givenname: Fan-Lin surname: Wu fullname: Wu, Fan-Lin – sequence: 4 givenname: Yan-Ming surname: Wei fullname: Wei, Yan-Ming – sequence: 5 givenname: Ci-Dan surname: Laba fullname: Laba, Ci-Dan – sequence: 6 givenname: Cuo-Mu surname: Wujin fullname: Wujin, Cuo-Mu – sequence: 7 givenname: Yong-Li surname: Hua fullname: Hua, Yong-Li – sequence: 8 givenname: Zi-Wen surname: Yuan fullname: Yuan, Zi-Wen – sequence: 9 givenname: Wan-Ling surname: Yao fullname: Yao, Wan-Ling |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38245694$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFks1u1TAQhSMEoqX0BVggS0iITYp_EsdZVhU_lVqxoKytiT25121iX2wH1JfhWfHtLVVbIZAXtkbfOTManxfVUx88VtUrRo8YU_J9Yrynsqa8qWkjGl6LJ9U-l5LXnezY03vvveowpUtKKRdMdKJ9Xu0JxZtW9s1-9esczRq8S3Mim4jWmex-IAkjuXADZvDkfFt0HsnXsFmHCGQOIZoYxuzAA4HpCqbgbCJjiCRHhDyjz1uHafErYsAbjGSAhJYET_Iaicf8M8QrsllDnMGEKayuCXhbrCc0ywSR2GCunF-9rJ6NMCU8vL0Pqm8fP1ycfK7Pvnw6PTk-q03b8VxbZeVIBVgpkRkrjaJSNcxQ1ghLubUglOFMAB3kgD0FbrtG8K7AgnWGioPqdOdrA1zqTXQzxGsdwOmbQogrDTE7M6HuBonjYAGtGptGKmWN6u3YcMMlNX1bvN7tvDYxfF8wZT27ZHCawGNYkhasLd9AW6X-i_KedW3LpOoK-uYRehmW6MtSCsXbVlLV3KNWUEZ1fgw5gtma6uNOcdZLduN19BeqHIuzMyVnoyv1B4K39wRrhCmvU5iW7IJPD8HXt1Muw4z2bpN_AlcAvgNKglKKON4hjOptsPUu2LoEW98EW4siUo9ExmXYNi9zu-lf0t8Lc_u_ |
| CitedBy_id | crossref_primary_10_3389_fmed_2024_1422306 crossref_primary_10_3390_ph17040429 |
| Cites_doi | 10.3390/genes13050786 10.7150/ijbs.20052 10.1016/j.mrfmmm.2020.111704 10.1038/onc.2015.296 10.1016/j.canlet.2013.11.001 10.1073/pnas.1934283100 10.1080/21655979.2022.2043099 10.1016/j.freeradbiomed.2011.09.035 10.1007/s11033-019-04982-6 10.3389/fnut.2022.1014414 10.1155/2018/4050714 10.1080/21655979.2022.2049958 10.1007/s10616-016-9947-4 10.3322/caac.21492 10.1080/21691401.2019.1699813 10.1111/1759-7714.13925 |
| ContentType | Journal Article |
| Copyright | 2024. The Author(s). COPYRIGHT 2024 BioMed Central Ltd. 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2024. The Author(s). – notice: COPYRIGHT 2024 BioMed Central Ltd. – notice: 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | AAYXX CITATION NPM 3V. 7TK 7U7 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BENPR C1K CCPQU COVID DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 7S9 L.6 DOA |
| DOI | 10.1186/s12906-024-04342-3 |
| DatabaseName | CrossRef PubMed ProQuest Central (Corporate) Neurosciences Abstracts Toxicology Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability (subscription) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central Environmental Sciences and Pollution Management ProQuest One Community College Coronavirus Research Database ProQuest Central Health Research Premium Collection (UHCL Subscription) Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic AGRICOLA AGRICOLA - Academic DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China Environmental Sciences and Pollution Management ProQuest Central ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Toxicology Abstracts ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Hospital Collection Health Research Premium Collection (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | AGRICOLA Publicly Available Content Database PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2662-7671 1472-6882 |
| EndPage | 47 |
| ExternalDocumentID | oai_doaj_org_article_7b6efbdaed8f44688dc89df42c260c95 A782196187 38245694 10_1186_s12906_024_04342_3 |
| Genre | Journal Article |
| GeographicLocations | China |
| GeographicLocations_xml | – name: China |
| GrantInformation_xml | – fundername: industry support project of colleges and universities in Gansu province grantid: 2020C-14 – fundername: discipline construction special fund project of Gansu Agricultural University grantid: Gau-xkjs-2018-068 – fundername: National beef/yak industrial technology system grantid: CARS-37 – fundername: National Natural Science Foundation of China grantid: 32260899 – fundername: Key R&D Projects of Ningxia Science and Technology Department grantid: 2023BCF01039 – fundername: Fuxi talent project of Gansu Agricultural University grantid: Gaufx-02y05 – fundername: Science and technology program of Tibet Autonomous Region grantid: XZ201901NA02 |
| GroupedDBID | 53G 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABUWG ADUKV AEUYN AFKRA AFPKN ALMA_UNASSIGNED_HOLDINGS BENPR BMC C6C CCPQU CITATION EBLON EBS EMB EMOBN FYUFA GROUPED_DOAJ HMCUK IAO IHR IHW INH ITC M1P M~E PGMZT PHGZM PHGZT PIMPY PSQYO ROL RPM RSV SOJ SV3 UKHRP NPM PJZUB PPXIY PMFND --- 0R~ 23N 2WC 3V. 5VS 6J9 6PF 7TK 7U7 7XB 8FK A8Z AAHBH AAWTL ACGFO ACGFS ACMJI ACPRK ADBBV ADRAZ AENEX AFRAH AHBYD AHMBA AHYZX ALIPV AMKLP AOIJS AZQEC BAWUL BCNDV BFQNJ BPHCQ BVXVI C1K COVID CS3 DIK DU5 DWQXO E3Z F5P GX1 HYE INR K9. KQ8 O5R O5S OVT P2P PKEHL PQEST PQQKQ PQUKI PRINS PROAC RBZ RNS SMD TR2 UNMZH W2D WOQ WOW XSB 7X8 7S9 L.6 PUEGO |
| ID | FETCH-LOGICAL-c572t-d8d6f03ad66e1cd6c806841c0143d02dda38c213a0b6be90a2d74327e1c317c03 |
| IEDL.DBID | 7X7 |
| ISSN | 2662-7671 |
| IngestDate | Wed Aug 27 01:24:00 EDT 2025 Fri Jul 11 09:25:42 EDT 2025 Mon Jul 21 10:49:55 EDT 2025 Mon Jun 30 11:59:06 EDT 2025 Tue Jun 17 22:25:38 EDT 2025 Tue Jun 10 21:13:56 EDT 2025 Thu May 22 21:20:55 EDT 2025 Mon Jul 21 05:19:52 EDT 2025 Tue Jul 01 03:51:55 EDT 2025 Thu Apr 24 23:00:15 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Alkaloids Network pharmacology Sophora Moorcroftiana Vitro Verification Lung cancer Molecular docking |
| Language | English |
| License | 2024. The Author(s). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c572t-d8d6f03ad66e1cd6c806841c0143d02dda38c213a0b6be90a2d74327e1c317c03 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://www.proquest.com/docview/2925560847?pq-origsite=%requestingapplication% |
| PMID | 38245694 |
| PQID | 2925560847 |
| PQPubID | 44230 |
| PageCount | 1 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_7b6efbdaed8f44688dc89df42c260c95 proquest_miscellaneous_3153730588 proquest_miscellaneous_2917551687 proquest_journals_2925560847 gale_infotracmisc_A782196187 gale_infotracacademiconefile_A782196187 gale_healthsolutions_A782196187 pubmed_primary_38245694 crossref_primary_10_1186_s12906_024_04342_3 crossref_citationtrail_10_1186_s12906_024_04342_3 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-01-20 |
| PublicationDateYYYYMMDD | 2024-01-20 |
| PublicationDate_xml | – month: 01 year: 2024 text: 2024-01-20 day: 20 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | BMC complementary and alternative medicine |
| PublicationTitleAlternate | BMC Complement Med Ther |
| PublicationYear | 2024 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | HZ Du (4342_CR3) 2020; 18 MC Li (4342_CR16) 2015; 50 X Jiang (4342_CR26) 2017; 48 H Guo (4342_CR41) 2021; 12 ZD Ding (4342_CR35) 2019; 36 YS Seo (4342_CR34) 2018; 39 B Liu (4342_CR40) 2020; 15 SY Wang (4342_CR13) 2014 Z Wang (4342_CR29) 2022; 28 B Vurusaner (4342_CR42) 2012; 52 BY Zhang (4342_CR12) 2022; 20 YC Li (4342_CR32) 2014; 344 W Yao (4342_CR36) 2022; 13 T Tian (4342_CR30) 2018; 16 SJ Wang (4342_CR20) 2017; 2017 J Xie (4342_CR11) 2019; 50 N Kim (4342_CR31) 2015; 2015 H Tang (4342_CR37) 2022; 13 Z Lin (4342_CR18) 2011 M Yang (4342_CR8) 2018; 2018 XC Duan (4342_CR9) 2020; 36 X Liu (4342_CR4) 2022; 20 XM Ma (4342_CR7) 2003; 39 DJ Yu (4342_CR24) 2020; 24 J Jen (4342_CR39) 2016; 35 NS Zhao (4342_CR6) 2020; 32 X Ding (4342_CR45) 2019; 22 QH Wang (4342_CR21) 2018; 24 J Chen (4342_CR27) 2022; 23 F Bray (4342_CR1) 2018; 68 BB Fang (4342_CR17) 2018; 26 X Li (4342_CR10) 2023; 21 C Orhan (4342_CR23) 2019; 465 JH Liao (4342_CR2) 2019; 26 M Farhan (4342_CR44) 2017; 13 C Eroğlu (4342_CR38) 2016; 68 YJ Ji (4342_CR5) 2019; 38 L Mu (4342_CR19) 2013; 30 WT Xu (4342_CR15) 2020; 2020 XH Zhang (4342_CR22) 2015; 36 RY Yuan (4342_CR14) 2016; 31 X Wang (4342_CR33) 2022; 13 S Singh (4342_CR25) 2020; 821 H Matsuzaki (4342_CR43) 2003; 100 C Porta (4342_CR28) 2014; 14 |
| References_xml | – volume: 24 start-page: 4288 year: 2020 ident: 4342_CR24 publication-title: Eur Rev Medi Pharmacolog Sci – volume: 13 year: 2022 ident: 4342_CR36 publication-title: Genes doi: 10.3390/genes13050786 – volume: 39 start-page: 1702 year: 2018 ident: 4342_CR34 publication-title: Oncol Rep – volume: 18 start-page: 206 year: 2020 ident: 4342_CR3 publication-title: Chin J Nat Med – volume: 13 start-page: 815 year: 2017 ident: 4342_CR44 publication-title: Int J Biol Sci doi: 10.7150/ijbs.20052 – volume: 2017 start-page: 1545 issue: 40 year: 2017 ident: 4342_CR20 publication-title: Drug Evaluation Research – volume: 26 start-page: 1096 year: 2019 ident: 4342_CR2 publication-title: Chin J Cancer Preve Treat – volume: 821 start-page: 111704 year: 2020 ident: 4342_CR25 publication-title: Mutat Res doi: 10.1016/j.mrfmmm.2020.111704 – volume: 48 start-page: 454 year: 2017 ident: 4342_CR26 publication-title: J Shanxi Medic Univer – volume: 50 start-page: 1111 year: 2015 ident: 4342_CR16 publication-title: J Chin Pharmaceutical – volume: 23 start-page: 22 year: 2022 ident: 4342_CR27 publication-title: BMC Complement Med Ther – volume: 35 start-page: 2357 year: 2016 ident: 4342_CR39 publication-title: Oncogene doi: 10.1038/onc.2015.296 – volume: 344 start-page: 239 year: 2014 ident: 4342_CR32 publication-title: Cancer Lett doi: 10.1016/j.canlet.2013.11.001 – volume: 32 start-page: 1614 year: 2020 ident: 4342_CR6 publication-title: Nat Prod Research Develop – volume: 100 start-page: 11285 year: 2003 ident: 4342_CR43 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1934283100 – volume: 16 start-page: 6133 year: 2018 ident: 4342_CR30 publication-title: Oncol Lett – volume: 20 start-page: 332 year: 2022 ident: 4342_CR12 publication-title: Chin J Nat Med – volume: 13 start-page: 6866 year: 2022 ident: 4342_CR33 publication-title: Bioengineered doi: 10.1080/21655979.2022.2043099 – volume: 36 start-page: 303 year: 2020 ident: 4342_CR9 publication-title: Chin Pharmacol Bull – volume: 52 start-page: 7 year: 2012 ident: 4342_CR42 publication-title: Free Radic Biol Med doi: 10.1016/j.freeradbiomed.2011.09.035 – volume: 21 start-page: 113 year: 2023 ident: 4342_CR10 publication-title: Chin J Nat Med – volume: 465 start-page: 5251 year: 2019 ident: 4342_CR23 publication-title: Mol Biol Rep doi: 10.1007/s11033-019-04982-6 – volume-title: Chemical constituents against drug-resistant staphylococcus aureus from Sophora moorcroftiana and Rheum officinale year: 2014 ident: 4342_CR13 – volume-title: Anti-tumor effects of alkaloids from TCM sophora plants year: 2011 ident: 4342_CR18 – volume: 39 start-page: 74 year: 2003 ident: 4342_CR7 publication-title: J Lanzhou University – volume: 28 start-page: 1014414 year: 2022 ident: 4342_CR29 publication-title: Front Nutr doi: 10.3389/fnut.2022.1014414 – volume: 30 start-page: 1580 year: 2013 ident: 4342_CR19 publication-title: Chin J Experimental Surg – volume: 31 start-page: 73 year: 2016 ident: 4342_CR14 publication-title: J Tibet Univers – volume: 38 start-page: 47 year: 2019 ident: 4342_CR5 publication-title: Chin & Foreign Medic Treatment – volume: 50 start-page: 2257 year: 2019 ident: 4342_CR11 publication-title: Chin Traditional Herbal Drugs – volume: 24 start-page: 31 year: 2018 ident: 4342_CR21 publication-title: Guiding J Traditional Chin Med Pharm – volume: 2018 year: 2018 ident: 4342_CR8 publication-title: Evid Based Complement Alternat Med. doi: 10.1155/2018/4050714 – volume: 13 start-page: 9284 year: 2022 ident: 4342_CR37 publication-title: Bioengineered doi: 10.1080/21655979.2022.2049958 – volume: 68 start-page: 2075 year: 2016 ident: 4342_CR38 publication-title: Cytotechnology doi: 10.1007/s10616-016-9947-4 – volume: 68 start-page: 394 year: 2018 ident: 4342_CR1 publication-title: CA Cancer J Clin doi: 10.3322/caac.21492 – volume: 20 start-page: 814 year: 2022 ident: 4342_CR4 publication-title: Chin J Nat Med – volume: 2015 start-page: 2397642015 year: 2015 ident: 4342_CR31 publication-title: Biomed Res Int – volume: 36 start-page: 485 year: 2019 ident: 4342_CR35 publication-title: Chin J Experimental Surg – volume: 14 start-page: 64 year: 2014 ident: 4342_CR28 publication-title: Front Oncol – volume: 2020 start-page: 84 issue: 48 year: 2020 ident: 4342_CR15 publication-title: Artif Cells Nanomed Biotechnol doi: 10.1080/21691401.2019.1699813 – volume: 15 start-page: 114848 year: 2020 ident: 4342_CR40 publication-title: Toxicol Appl Pharmacol – volume: 12 start-page: 1415 year: 2021 ident: 4342_CR41 publication-title: Thorac Cancer doi: 10.1111/1759-7714.13925 – volume: 36 start-page: 660 year: 2015 ident: 4342_CR22 publication-title: Guangdong Med J – volume: 22 start-page: 491 year: 2019 ident: 4342_CR45 publication-title: Iran J Basic Med Sci – volume: 26 start-page: 1811 year: 2018 ident: 4342_CR17 publication-title: J Mod Oncol |
| SSID | ssj0002313735 ssj0017814 |
| Score | 2.2655928 |
| Snippet | Leguminous Sophora moorcroftiana (SM) is a genuine medicinal material in Tibet. Many research results have reveal the Sophora moorcroftiana alkaloids (SMA), as... Background Leguminous Sophora moorcroftiana (SM) is a genuine medicinal material in Tibet. Many research results have reveal the Sophora moorcroftiana... BackgroundLeguminous Sophora moorcroftiana (SM) is a genuine medicinal material in Tibet. Many research results have reveal the Sophora moorcroftiana alkaloids... BACKGROUND: Leguminous Sophora moorcroftiana (SM) is a genuine medicinal material in Tibet. Many research results have reveal the Sophora moorcroftiana... Abstract Background Leguminous Sophora moorcroftiana (SM) is a genuine medicinal material in Tibet. Many research results have reveal the Sophora moorcroftiana... |
| SourceID | doaj proquest gale pubmed crossref |
| SourceType | Open Website Aggregation Database Index Database Enrichment Source |
| StartPage | 47 |
| SubjectTerms | 1-Phosphatidylinositol 3-kinase active ingredients AKT protein Alkaloids Anticancer properties Antiparasitic agents Antitumor activity Binding Biological activity biosynthesis Cancer Care and treatment Cell proliferation China Chromatin complement computer software Cytoplasm Disease Drug therapy Encyclopedias Enrichment enzymes ESR1 protein exosomes Forkhead protein gene ontology Gene regulation Genes Genetic transcription genome Genomes Genomics Health services Ligands Lung cancer lung neoplasms mechanism of action Molecular docking Mortality Network pharmacology Nitric oxide Non-small cell lung carcinoma Notch1 protein Online databases Oriental traditional medicine p53 Protein Pharmacology Prevention Protein interaction Protein-protein interactions Proteins Regulatory mechanisms (biology) Respiratory agents Sophora Sophora Moorcroftiana Therapeutic targets therapeutics Traditional Chinese medicine transcription factors Tumor proteins Vitro Verification |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9RADB6hHhAXxJtAASMhcUBRk5lkMjkWRFUhLRdaqbfRPMXCNllttgf-DL8Ve5INXZDKhWviiRLbY39J7M-MvalrLm3leC54lNSS4_KWR58L2SqLHhBj6q1afJan59Wni_ri2qgvqgkb6YFHxR01VoZovQle4TKplHeq9bHiDpG4axN7Kea8ay9T3xKJSykaUe-6ZJQ8GuiDC9XbUt2FqPDm9jJRIuz_Oyz_ATZT0jm5x-5OaBGOx7u8z26F7gG7vZj-hz9kPxeBOneXw-UA6w0dpugFfYSzpQ2I-2AnC1_69Vc0N1z2_SYFX_QLA2b13az6pR8AwSvMVed0hRWGAXDkFBugXOeh7wDhInRj5Tisf7Ne_wDTebz0NGoXPEZZzImP2PnJx7MPp_k0cSF3dcO3uVdexkIYL2UonZdOFVJVpSMSQF9w741QjpfCFFba0BaGe0QgvEFhxCGuEI_ZQdd34SmDCpGGs8Gg1kVVm9rEEJxpYyF9EZUyGSt32tduoiOnqRgrnV5LlNSjxTRaTCeLaZGxd_Oa9UjGcaP0ezLqLElE2ukAupee3Ev_y70y9opcQo9dqXM40MeIrEqaltNk7G2SoICAD-DM1NeAaiBqrT3Jwz1J3Mhu__TO7fQUSAbNW-KIKxBDZOz1fJpWUnFcF_orkkEMWJdS3SAjMLNhMK-VytiT0aVnxQhFf7_b6tn_UNhzdoenTVZiAD5kB9vNVXiBuG1rX6Yt-gsbqUBA priority: 102 providerName: Directory of Open Access Journals |
| Title | Mechanisms predictive of Tibetan Medicine Sophora moorcroftiana alkaloids for treatment of lung cancer based on the network pharmacology and molecular docking |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/38245694 https://www.proquest.com/docview/2925560847 https://www.proquest.com/docview/2917551687 https://www.proquest.com/docview/3153730588 https://doaj.org/article/7b6efbdaed8f44688dc89df42c260c95 |
| Volume | 24 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1ba9swFBZbC2MvY_e56zINBnsYprZkK_LTaEZLGaSMroWwFyHrsoWldhanD_0z-607R1ZcskFe8mAfG0fn6NOno3Mh5H1ZMlEXhqWceYEpOSatmLcpF5WswQK8D7lV03NxdlV8mZWz6HDrYljlBhMDUNvWoI_8iFVYLCsDMP20_J1i1yg8XY0tNO6TfSxdhiFd49mw4cqxnNMmUUaKow59Lhhyi6EXvIDv21qMQs3-_5H5H74Z1p3Tx-RRJIz0uNfwE3LPNU_Jg2k8En9G_kwdJu_Ou-uOLld4GQGMtp5ezmsH1I9uZOm3dvkTNE6v23YV8BdMQ1O9-KUX7dx2FPgrHQLP8Q0LQAJq0C5WFJc7S9uGAmOkTR88Tpd3ha9vqW4svDp226UwouiFf06uTk8uP5-lselCasoxW6dWWuEzrq0QLjdWGJkJWeQG6wDajFmruTQs5zqrRe2qTDMLJISNQRioiMn4C7LXtI17RWgBZMPUTsOo86LUpfbOGV35TNjMS6kTkm9GX5lYkRwbYyxU2JlIoXqNKdCYChpTPCEfh2eWfT2OndITVOogibW0w4V29UPFqanGtXC-ttpZCYYppLRGVtYXzMBez1RlQt6iSag-MXVABHUM5CrHhjnjhHwIEogJ8AeMjqkNMAxYXWtL8nBLEuay2b69MTsVsaRTd5afkHfDbXwS4-Ma196gDNDAMhdyhwyHxQ3wvJQyIS97kx4Ghks8AK-Kg90f8Jo8ZGH65ICuh2Rvvbpxb4CUretRmHkjsj85Of96MQquDfi9mHwfBQ_aX26tOn8 |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZGJwEviDuBwYwE4gFFS-zEdR4Q2mBTx9YKQSftzXNsByq6pCSd0P4MP4HfyDm5TQWpb3tNTqz2XL5zbJ8LIa_imIk0MsznLBNYkmP8hGXW5yKRKWhAltW1VeOJGJ1En07j0w3yp6uFwbTKDhNroLaFwTPyHZZgs6wAwPT94qePU6PwdrUbodGoxZG7_AVbturd4UeQ72vGDvanH0Z-O1XAN_GQLX0rrcgCrq0QLjRWGBkIGYUGG93ZgFmruTQs5DpIReqSQDMLXpYNgRh8rQk4rHuDbEYctjIDsrm3P_n8pb-3wAZSXWmOFDsVnvJgki8me_AIOLLi_uopAf_7gn8i3NrTHdwld9oQle42OnWPbLj8Prk5bi_hH5DfY4flwrPqvKKLEh8jZNIio9NZ6iDYpB0t_VosvoOO0fOiKGvEB2XUVM9_6HkxsxWFiJn2qe64whywhxrUxJKig7W0yCnEqDRv0tXp4qrV9iXVuYWl2_m-FGSI5_4Pycm1COQRGeRF7p4QGkF4Y1Knges8inWsM-eMTrJA2CCTUnsk7LivTNsDHUdxzFW9F5JCNRJTIDFVS0xxj7ztv1k0HUDWUu-hUHtK7N5dPyjKb6oFAzVMhctSq52VYApCSmtkYrOIGdhdmiT2yDaqhGpKYXsMUrsQzoU4omfokTc1BaIQ_AGj22IKYAP281qh3FqhBPQwq687tVMtelXqytY88rJ_jV9iRl7uigukgcAzDoVcQ8PBnYIHiaX0yONGpXvGcIlX7kn0dP0P2Ca3RtPxsTo-nBw9I7dZbUohYPsWGSzLC_ccQsJl-qK1Q0rOrtv0_wIkZ3OK |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mechanisms+predictive+of+Tibetan+Medicine+Sophora+moorcroftiana+alkaloids+for+treatment+of+lung+cancer+based+on+the+network+pharmacology+and+molecular+docking&rft.jtitle=BMC+complementary+medicine+and+therapies&rft.au=Ji%2C+Peng&rft.au=Zhao%2C+Nian-Shou&rft.au=Wu%2C+Fan-Lin&rft.au=Wei%2C+Yan-Ming&rft.date=2024-01-20&rft.pub=BioMed+Central+Ltd&rft.issn=2662-7671&rft.eissn=2662-7671&rft.volume=24&rft.issue=1&rft_id=info:doi/10.1186%2Fs12906-024-04342-3&rft.externalDocID=A782196187 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2662-7671&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2662-7671&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2662-7671&client=summon |